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Abstract
We report clinical outcomes following transcatheter aortic valve implantation (TAVI), using the CoreValve revalving system (18 Fr
transfemoral or subclavian) or the Edwards Sapien valve (22 Fr transfemoral or 24 Fr transapical) as part of a Belgian prospective non-
randomized multicentre registry. All 15 Belgian centres performing TAVI participated to this registry (seven exclusively Edwards Sapien,
eight exclusively CoreValve). All consecutive high-risk symptomatic patients with severe aortic stenosis were evaluated by a heart team
and screened for eligibility for TAVI. Three hundred and twenty-eight patients underwent TAVI with CoreValve (ns141; eight subclavian
and 133 transfemoral) or Edwards Sapien (ns187; 99 transfemoral and 88 transapical) up to April 2010. Procedural success was 97%. One-
month survival was 88% for the Edwards and 89% for the CoreValve treated patients. One-month mortality was both related to cardiac and
non-cardiac reasons. Overall one-year survival was 78% in the CoreValve transfemoral treated patients, 100% in the CoreValve subclavian
treated patients, 82% in the Edwards transfemoral treated patients and 63% in the Edwards transapical treated patients. This mid-term
mortality was mainly related to age-related, non-cardiac complications.
 2011 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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1. Introduction
Surgical aortic valve replacement (SAVR) is the primary
treatment modality recommended for severe aortic steno-
sis, offering both symptomatic and prognostic benefits.
However, the need for a less-invasive, non-surgical treat-
ment option for high-risk patients has recently culminated
in development of transcatheter aortic valve implantation
(TAVI). Currently, two devices are clinically in use. The
Edwards Sapien valve is a bovine pericardium prosthesis
mounted on a balloon-expandable stent that is placed in
the subcoronary position. It can be placed by an antegrade
(transapical) or retrograde (transfemoral) approach. The
CoreValve transcatheter aortic valve is a self-expanding
nitinol frame porcine pericardium prosthesis, placed by a
retrograde (transfemoral or subclavian) approach.
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Randomized trials that are currently underway will con-
firm procedural safety and guide the applicability of this
technology. In the mean time, carefully performed national
registries monitoring all TAVI outcome data of both devices
can already be of value in defining the potential clinical
role of this new technology in high-risk symptomatic
patients refused for SAVR w1–4x. The Belgian TAVI Registry
is a prospective, non-randomized multicenter national reg-
istry, aiming to include and follow-up all consecutive Bel-
gian TAVI procedures.
2. Methods
2.1. The Belgian TAVI Registry
All 15 Belgian cardiac centres, performing TAVI, partici-
pated to this Belgian TAVI Registry. In seven of these
centres, the Edwards Sapien valve was exclusively used and
in eight of these, the CoreValve device was exclusively
used. All consecutive TAVI procedures were included.
Patient follow-up was obtained during and immediately
after valve implantation, and at 1, 6 and 12 months.
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Table 1. Patient characteristics
Edwards Sapien (ns187) CoreValve (ns141) Total population (ns328) P-value
Age (years) 83"6 82"6 83"6 0.17
Gender (, %) 47 44 46 0.60
NYHA III, IV (%) 80 78 79 0.085
AVA (cm )2 0.59"0.15 0.63"0.13 0.61"0.15 0.073
Mean grad (mmHg) 48"16 49"16 49"16 0.67
LVEF (%) 52"15 59"13 55"14 0.000
Log EuroSCORE (%) 30"16 25"15 28"16 0.003
Atrial fibrillation (%) 32 27 30 0.33
Carotid disease (%) 27 10 20 0.000
CAD (%) 59 57 58 0.78
Porcelain aorta (%) 7 9 8 0.51
PVD (%) 38 18 29 0.000
Diabetes (%) 29 25 27 0.43
Pulm hypertension (%) 53 41 48 0.029
Mediastinal radiation (%) 4 6 5 0.48
COPD (%) 32 22 28 0.039
Renal failure (%) 22 18 20 0.41
Previous strokeyTIA (%) 20 9 15 0.006
Previous PM (%) 13 14 13 0.81
Previous CABG (%) 25 29 26 0.33
Previous valve surgery (%) 3 2 3 0.73
AVA, aortic valve area; LVEF, left ventricular ejection fraction; CAD, coronary artery disease; PVD, peripheral vascular disease; COPD, chronic obstructive
pulmonary disease; TIA, transient ischemic attack; PM, pacemaker; CABG, coronary artery bypass grafting; NYHA, New York Heart Association.
Table 2. Procedural characteristics and outcome
n (%) Edwards Sapien (ns187) CoreValve (ns141) Total population (ns328) P-value
Access TF 99 (53) 133 (94) 232 (71) 0.000
Access TA 88 (47) 0 (0) 88 (27) 0.000
Access SC 0 (0) 8 (6) 8 (2) 0.000
Frame size
23 mm 73 (39)
26 mm 114 (61) 56 (40)
29 mm 85 (60)
Valve migration 5 (3) 4 (3) 9 (3) 1.00
Valve-in-valve 1 (0.5) 3 (2) 4 (1) 085
Procedural success 181 (97) 138 (98) 319 (97) 0.73
Procedural mortality 6 (3) 3 (2) 9 (3) 0.73
TF, transfemoral; TA, transapical; SC, subclavian.
Collection of patient data for the Belgian TAVI Registry
was approved by the institutional Ethics Committee of the
different participating centres.
Events and values collected are site recorded, and there
are no core laboratories. Data pooling and statistical anal-
ysis was performed at the University of Antwerp.
2.2. Patients
TAVI was considered by the heart team in symptomatic
patients with significant aortic valve stenosis who were not
good candidates for surgical aortic valve replacement.
2.3. Statistical analysis
Continuous variables are presented as means ("S.D.) and
were compared with the use of Student’s t-test. In case of
non-normal distribution, Mann–Whitney test was used. Cat-
egorical variables were compared with the use of Fisher’s
exact test. Survival curves for time-to-event variables were
constructed on the basis of all available follow-up data
with the use of Kaplan–Meier estimates and were compared
with the use of the log-rank test.
3. Results
3.1. Patient population
Three hundred and twenty-eight consecutive patients who
underwent TAVI until April 2010 were enrolled in this
registry. Of the 187 Edwards treated patients, 53% (ns99)
was treated transfemoral and 47% (ns88) by transapical
approach. Of the 141 CoreValve treated patients, 94%
(ns133) was treated transfemoral, and 6% (ns8) by sub-
clavian approach. Baseline characteristics of the patients
are reported in Table 1.
3.2. Procedural results and one-month clinical events
and survival
Procedural success (Table 2) was very high in both treat-
ment groups wEdwards (97%); CoreValve (98%); non-signifi-
cant (NS)x. Procedural mortality was 3% in the Edwards
treated patients and 2% in the CoreValve treated patients
(non-significant, NS). Reasons of procedural mortality are
summarized in Table 3. One month outcome data are
summarized in Table 4.
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Table 5. Causes of mortality (procedural mortality not included)
ns28 Cardiac (ns15) Non-cardiac (ns13)
-1 Month Late tamponade (3) Stroke or IC bleeding (5)
Conduction disturbances with arrest (4) Ischemic colitis (1)
AR-heart failure (2) Multi-organ failure (2)
Heart failure (3) Pneumonia – sepsis (3)
Sudden death (3) Bleeding complications (2)
ns28 Cardiac (ns8) Non-cardiac (ns20)
1 Month–1 year Heart failure (5) Pneumonia (5)
Acute resp failure (2)




Trauma – IC bleeding (1)
Hip fracture (3)
AR, aortic regurgitation; IC, intracranial.
Table 4. One month outcome data
n (%) Edwards Sapien CoreValve Total population P-value
New pacemaker 9y181 (5) 31y138 (22) 40y319 (13) 0.000
Renal failure needing dialysis 10y181 (6) 9y138 (7) 19y319 (6) 0.096
Clinical stroke 9y181 (5) 5y138 (4) 14y319 (5) 0.67
TIA 2y181 (1) 1y138 (1) 3y319 (1) 0.57
One-month survival 165y187 (88) 126y141 (89) 291y328 (89) 0.99
One-month mortality 22y187 (12) 15y141 (11) 37y328 (11) 0.99
TIA, transient ischemic attack.
The need for a new definitive pacemaker implantation
was significantly higher in the CoreValve treated patients
compared to the Edwards treated patients. The incidence
of renal failure (meaning dialysis needed), clinical stroke
or transient ischemic attack (TIA) within the first month
after TAVI was comparable between both treatment groups.
One-month survival was 88% for the Edwards and 89% for
the CoreValve treated patients (NS). Causes of mortality
are summarized in Table 5 and almost equally distributed
between cardiac and non-cardiac reasons.
3.3. One-year clinical events and survival
One year clinical outcome data are summarized in Fig. 1.
Overall one-year survival was 78% in the CoreValve trans-
femoral treated patients, 100% in the CoreValve subclavian
treated patients, 82% in the Edwards transfemoral treated
patients and 63% in the Edwards transapical treated
patients. Causes of mortality within the first year are
summarized in Table 5 and mainly related to non-cardiac
reasons.
3.4. Edwards Sapien transfemoral vs. transapical
treated patients: patient characteristics and
long-term outcome
Data are summarized in Table 6 and Fig. 1. One-year
survival of the transapically treated Edwards Sapien
patients was significantly less compared to the transfemor-
ally treated patients.
3.5. One-year echographic follow-up
Data are summarized in Fig. 2 and based on complete
one-year echographic follow-up in 117 patients (60 Core-
Valve and 57 Edwards Sapien). Post-procedural transaortic
pressure gradients were markedly low in both groups.
During the first year after TAVI, no significant deterioration
of the gradients was documented. No prosthetic structural
deterioration or non-structural dysfunction was observed.
4. Discussion
Waiting final conclusions of randomized trials, carefully
performed national registries, monitoring acute and long-
term safety and efficacy results, both of CoreValve (trans-
femoral, subclavian) and Edwards (transfemoral,
transapical) TAVI treated patients are of importance in
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Fig. 1. Kaplan–Meier survival curves, expressing one-year survival after TAVI. TAVI, transcatheter aortic valve implantation; TF, transfemoral; TA, transapical;
SC, subcalvian.
Table 6. Edwards Sapien transfemoral vs. transapical
Patient characteristics Edwards Sapien Edwards Sapien P-value
transfemoral (ns99) transapical (ns88)
Age (years) 84"5 82"6 0.011
LVEF (%) 51"16 51"14 0.98
Log EuroSCORE (%) 29"15 33"17 0.101
Carotid dis n (%) 11 (11) 16 (14) 0.020
Diabetes n (%) 10 (10) 19 (18) 0.31
PVD n (%) 4 (4) 34 (30) 0.000
Porcelain ao n (%) 2 (2) 5 (4) 0.000
Prev CABG n (%) 5 (5) 20 (18) 0.002
One month MACE
Pacemaker n (%) 4y96 (4) 5y85 (6) 0.19
Renal failure n (%) 2y96 (2) 8y85 (9) 0.005
Stroke n (%) 2y96 (2) 7y85 (8) 0.047
LVEF, left ventricular ejection fraction; PVD, peripheral arterial disease; ao,
aorta; prev CABG, previous coronary artery bypass grafts; carotid dis, carotid
disease.
understanding better possible clinical value of this new
treatment modality for high-risk patients.
4.1. The Belgian TAVI Registry
The Belgian TAVI Registry is a carefully conducted pro-
spective, non-randomized multicenter national registry,
aiming to include and follow-up all Belgian TAVI procedures.
In contrast to some other national or single centre regis-
tries, all consecutive TAVI patients in Belgium, both treated
by the Edwards Sapien valve or by the CoreValve prosthesis,
are included in this registry. Moreover, mid-term follow-up
was completed in a very high number of patients. If
possible, the reason of death was documented. Although
there is no formal central core laboratory, both the Belgian
Working Group for Interventional Cardiology and the Belgian
Working Group for Cardiac Surgery stimulated participating
sites for providing high-quality patient data.
4.2. Procedural results and one-month clinical events
and survival
After careful selection of patients with severe sympto-
matic aortic valve stenosis, refused for surgery and with
acceptable additional technical evaluation, TAVI can be
successfully performed in a high number of patients, with
low procedural mortality. This finding is confirmed by many
other similar registries w1–4x. The main reasons for proce-
dural mortality are related to suboptimal guidewire manip-
ulation wleading to left ventricle (LV) perforationx, sub-
optimal aortic root measurements (leading to severe aortic
valve regurgitation or annulus rupture) or major vascular
complications (bleeding or dissection).
One-month mortality after TAVI is almost equally distrib-
uted between cardiac and non-cardiac causes. Three
patients died due to suboptimal manipulation of the tem-
porary pacing electrode with severe tamponade and col-
lapse, while at least four others died due to too rapid
removal or dislocation of the pacing electrode with occur-
rence of conduction disturbances and arrest. This finding
focuses our attention to the need of improved post-proce-
dural care and better and more uniform guidelines to
pacemaker management after TAVI. Another two to five
patients died within the first weeks after TAVI due to severe
aortic valve regurgitation related to valveyannulus mis-
match or valve undersizing. This finding focuses on even
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Fig. 2. Echocardiographic follow-up of LV function (ejection fraction, EF) and
mean aortic valve gradient during the first year after TAVI. TAVI, transcath-
eter aortic valve implantation; LV, left ventricle.
more careful technical selection (evaluation of aortic root
dimensions) of potential TAVI patients. Finally, 13 patients
died due to non-cardiac complications of which some
(pneumonia, sepsis, «) are probably related to too high
frailty of selected patients.
4.3. Mid-term outcome after TAVI
One-year survival in this high-risk population is good,
mainly in the transfemorally and subclavian (only limited
group) CoreValve treated patients and the transfemorally
treated Edwards Sapien patients. Survival rates are proba-
bly significantly more, than what was predicted by different
risk scores in this patient population. Our registry demon-
strates that causes of mid-term mortality are mainly (20y
28) related to age-dependent complications and are
probably not related to, or cannot be prevented by TAVI.
Long-term cardiac mortality seems to be relatively low
after TAVI, in a patient population which was initially
strongly symptomatic with high chance of cardiac death.
Although non-randomized registries are not designed to
compare different treatment strategies, a remarkable
observation in our registry is the significantly higher mid-
term mortality of the transapically treated Edwards Sapien
patients, compared to the transfemorally treated Edwards
Sapien patients and the CoreValve treated patients. Wheth-
er this is related to different baseline patient characteris-
tics or to other procedural elements, cannot be answered
by our data.
4.4. Limitations
There were no centres performing both CoreValve and
Edwards procedures. The number of patients is relatively
limited, comparison of treatment strategies (Edwards Sap-
ien vs. CoreValve) (transfemoral vs. transapical) is not
mandatory in a non-randomized registry and there is no
central core laboratory monitoring all events.
5. Conclusions
Percutaneous aortic valve replacement for selected patients
with severe aortic valve stenosis is associated with a low
acute and mid-term mortality in a high-risk population.
Further progress in better technical patient selection, care-
ful post-procedural care and evaluation of most optimal
access are essential to improve actual results.
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Dr. M. Antunes (Coimbra, Portugal): Dr. Bosmans and colleagues, here
represented by Dr. Rodrigus, analyzed the Belgian prospective non-random-
ized multicenter registry of transcatheter aortic valve implantation (TAVI),
an emerging alternative for high-risk symptomatic patients with severe
aortic stenosis. The report included 328 consecutive high-risk symptomatic
patients, mean age 83 years and a logistic EuroSCORE of 28. There was a
high-procedural success of 97%, and one-month survival of 91% for both
types of valves. Overall, one-year survival was a little bit lower for the
transapically-treated patients.
These results are in keeping with current reports coming from most other
centers and prove the feasibility and reproducibility of the procedure, at
least in selected centers, but still leave open the question of median to
long-term results in comparison with the classical surgical AVR. Of impor-
tance, the paper does not give an insight into the number and percentage
of both techniques, and, even more importantly, does not shed any light on
the numbers and results of patients originally referred for TAVI because of
a too high-risk for surgery and ultimately operated on. Many recent series
of TAVI include groups of these patients who had better results than those
of the TAVI groups. I believe it is time to make a wide survey of both groups,
which would constitute the closest approximation to randomization that we
have until now.
As with other studies, this one bases its referral for TAVI on the logistic
EuroSCORE, which has now been clearly demonstrated to be of no value in
accurately predicting the risk of AVR because it consistently over-predicts it
by a factor of three or four, especially in the high-risk groups. And it is
interesting that the authors did not use the additive EuroSCORE or the STS
score (Society of Thoracic Surgeons), which are viewed as more accurate.
This could be interpreted as deliberate and, in my opinion, unfair, in my
opinion, not to say unethical, in bedevilling the surgical procedure for these
patients.
I have a couple of questions, then. The authors observed the usual high
incidence of 23% requirement for pacemaker implantation, 6% incidence of
stroke and TIA, and 6% incidence of renal failure. What are the reasons for
persisting with this valve, especially in view of the high incidence of
pacemaker requirement? Did you detect any advantage of one valve versus
the other since you have a large number for comparison of both valves?
Surprisingly for a selected group of patients and therefore closely followed,
the authors report an unknown cause of death in 14 early and, in the paper,
12 first-year deaths, nearly half of the total number of deaths. For a registry,
this is too high an incidence of death from unknown cause. What are the
reasons for this?
Finally, in the paper you state that the late mortality is essentially due to
age-related non-cardiac complications, but in this you included causes such
as endocarditis and stroke. Are these not cardiac-related? In many surgical
series reported, these would certainly be classified as such.
Dr. Rodrigus: The choice of the valve is a center decision. It has to do
with the concept of the valve and the belief you have in one of the two
concepts, I think. Furthermore, there are other issues playing a role, not
only the financial question. So that is a center decision. And I do not think
the high pacemaker need is reason not to use the CoreValve device.
And concerning the registration of mortality, this is a Belgian problem. We
do not have the same kind of databases as the UK. This registry started in
the first place to look at one-month median survival, and then obviously it
was of interest to have a longer follow-up. So we can only thank the
participants for trying to send in their data, but not every center is very
keen on finding out the cause of mortality of its patients.
Dr. M. Sousa Uva (Lisbon, Portugal): First question, have the Belgian
authorities changed their minds with these results? Because, as people
maybe do not know, the Health Technology Assessment in Belgium has
considered that TAVI should not be reimbursed. So that is my first question.
The second question. With these results, have the Belgian health authorities
changed their policy and now reimburse this procedure?
Dr. Rodrigus: No, not yet. Last year they stated that they will await the
results of the PARTNER trial. So we are hoping these results are very good
and that they will reimburse it.
